Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 2, 2014, Pages 469-478

  Sparve, Erik ^a   Quartino, Angelica L ^b   Lüttgen, Maria ^c   Tunblad, Karin ^d   Gårdlund, Anna Teiling ^e   Fälting, Johanna ^f   Alexander, Robert ^g   Kågström, Jens ^h   Sjödin, Linnea ⁱ   Bulgak, Alexander ^c   Al Saffar, Ahmad ^j   Bridgland Taylor, Matthew ^g   Pollard, Chris ^g   Swedberg, Michael D B ^k   Vik, Torbjörn ^l   Paulsson, Björn ^m  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GENENTECH INC   (United States)

^c Medical Product Agency   (Sweden)

^d MEDIVIR AB   (Sweden)

^e Kvegerö Gård ^*  (Sweden)

^f BioArctic Neuroscience   (Sweden)

^g ASTRAZENECA   (United Kingdom)

^h Centre for Clinical Research   (Sweden)

ⁱ HÖGANÄS AB   (Sweden)

^j UPPSALA UNIVERSITY   (Sweden)

^k Swedberg Preclinical Partner AB (Inc)   (Sweden)

^l ASTRAZENECA R AND D   (Sweden)

^m BIOVITRUM AB   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZD 3839; BETA SECRETASE INHIBITOR; UNCLASSIFIED DRUG; [1 [2 (DIFLUOROMETHYL)PYRIDIN 4 YL] 4 FLUORO 1 [3 (PYRIMIDIN 5 YL)PHENYL] 1H ISOINDOL 3 AMINE HEMIFUMARATE];

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERABILITY; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; IC 50; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ARTERIAL PRESSURE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; GUINEA PIGS; HUMANS; INDOLES; MALE; MODELS, BIOLOGICAL; PYRIMIDINES;

EID: 84904990379     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.215202     Document Type: Article

References (26)

1. Bergstrand M, Hooker AC, Wallin JE, and Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13: 143-151.
2. Bridgland-Taylor MH, Hargreaves AC, Easter A, Orme A, Henthorn DC, Ding M, Davis AM, Small BG, Heapy CG, and Abi-Gerges N, et al (2006) Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J Pharmacol Toxicol Methods 54:189-199.
3. Cavero I, Mestre M, Guillon J-M, and Crumb W (2000) Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 1:947-973.
4. Food and Drug Administration (2005) Guidance for Industry, E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Silver Spring, MD.
5. Fridericia LS (1920) The duration of systole in the electrocardiogram of normal subjects and of patients with heart disease. Acta Med Scand 53:469-486.
6. Gintant G (2011) An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 129: 109-119.
7. Jeppsson F, Eketjäll S, Janson J, Karlström S, Gustavsson S, Olsson LL, Radesäter AC, Ploeger B, Cebers G, and Kolmodin K, et al. (2012) Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem 287:41245-41257.
8. Kågström J, Sjögren E-L, and Ericson AC (2007) Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs. J Pharmacol Toxicol Methods 56:186-193.
9. Kang J, Chen XL, Wang H, Ji J, Reynolds W, Lim S, Hendrix J, and Rampe D (2004) Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 308:935-940.
10. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, and Benincosa LJ, et al (2007) Modelbased drug development. Clin Pharmacol Ther 82:21-32.
11. Lindbom L, Pihlgren P, and Jonsson EN (2005) PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NON-MEM. Comput Methods Programs Biomed 79:241-257.
12. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, and Watson BM, et al (2011) Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci 31:16507-16516.
13. Nerbonne JM and Kass RS (2005) Molecular physiology of cardiac repolarization. Physiol Rev 85:1205-1253.
14. Ollerstam A, Persson AH, Visser SA, Fredriksson JM, Forsberg T, Nilsson LB, Eklund G, Wiklund SJ, Gabrielsson J, and Duker G, et al (2007) A novel approach to data processing of the QT interval response in the conscious telemetered beagle dog. J Pharmacol Toxicol Methods 55:35-48.
15. Ollerstam A, Visser SAG, Persson AH, Eklund G, Nilsson LB, Forsberg T, Wiklund SJ, Gabrielsson J, Duker G, and Al-Saffar A (2006) Pharmacokinetic- pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs. J Pharmacol Toxicol Methods 53:174-183.
16. Quartino A, Huledal G, Sparve E, Lüttgen M, Bueters T, Karlsson P, Olsson T, Paraskos J, Maltby J, Claeson-Bohnstedt K, et al. (2014) Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers. Clin Pharmacol Drug Dev DOI: 10.1002/cpdd.130 [published ahead of print].
17. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, and Wallis R, et al (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45.
18. Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350: 1013-1022.
19. Schroeder K, Neagle B, Trezise DJ, and Worley J (2003) Ionworks HT: a new high-throughput electrophysiology measurement platform. J Biomol Screen 8:50-64.
20. Swahn BM, Kolmodin K, Karlström S, von Berg S, Söderman P, Holenz J, Berg S, Lindström J, Sundström M, and Turek D, et al. (2012) Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides. J Med Chem 55:9346-9361.
21. Tseng J, Dockendorf M, Krishna G, Ma L, Palcza J, Leempoels J, Ramael S, Han D, Jhee S, and Ereshefsky L, et al. (2012) Safety and pharmacokinetics of the novel BACE inhibitor MK-8931 in healthy subjects following single and multiple dose administration. Alzheimers Dement 8:S184-S185.
22. Vik T, Pollard C, and Sager P (2008) Early clinical development: evaluation of drug-induced torsades de pointes risk. Pharmacol Ther 119:210-214.
23. Wallis RM (2010) Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. Br J Pharmacol 159:115-121.
24. Yang T, Snyders D, and Roden DM (2001) Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 38:737-744.
25. Zhang L, Beal SL, and Sheiner LB (2003) Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 30:387-404.
26. Zhang S, Zhou Z, Gong Q, Makielski JC, and January CT (1999) Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84:989-998.